Cerezuela-Fuentes, P, Piñero-Madrona, A, Muñoz-Couselo, E, Manzano, JL, Berciano-Guerrero, MA, Majem, M, Espinosa, E, Soria, A, de Miguel, PA, Castaño, AG, Crespo, G, Sanz, LG, de la Rosa, CA, Fernández-Morales, LA, Puértolas, T, Rodríguez, JF, de la Borbolla, MR, Bellido, L, Castro, RL, Pérez, VN, Arroyo, FRG, Guzmán, JCV, Balea, BC, Hernández, B, Algarra, SM, Márquez-Rodas, I. Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801. Clinical & Translational Oncology. 2026; 28(6)DOI:10.1007/s12094-025-04164-w. PMID:41420791. IF:2.500(Q3/6D).

Montañá, JR, Roselló, S, Paez, D, Safont, MJ, Vidal, J, Gravalos, C, Polo, E, Jimenez-Fonseca, P, Calle, SG, Paredes, BG, Beltran, M, Gonzalo-Ruiz, J, Rosales, C, Palmer, HG, Garcia, DL, Nuciforo, P, Vivancos-Prellezo, A, Tabernero, J, Elez, E. Bevacizumab plus encorafenib-cetuximab in BRAF V600E mutated metastatic colorectal cancer (mCRC): A phase II study with a safety lead-in cohort (the BRAVE trial).. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.TPS3681. PMID:. IF:41.900(Q1/1D).

Martin-Broto, J, Martinez-Trufero, J, Diaz-Beveridge, R, Gutierrez, A, Carrasco, I, Lopez-Jimenez, C, Sebio, A, González-Billalabeitia, E, Ramos, R, Romagosa, C, Merino, J, Fernandez-Jara, J, Hernandez-Vargas, L, Garmendia, MD, Cruz-Jurado, J, Valverde, C, Mondaza-Hernandez, JL, Carrera, MA, Ledesma, P, Hindi, N, Moura, DS. Safety and Efficacy of Epirubicin, Ifosfamide, and Nivolumab as First-Line Treatment for Patients with Undifferentiated Pleomorphic Sarcoma. CLINICAL CANCER RESEARCH. 2026; 32(11)DOI:10.1158/1078-0432.CCR-26-0032. PMID:41817407. IF:10.200(Q1/1D).

Aviles, P, Ribeiro, ML, Guillén, MJ, Martinez-Diez, M, Muñoz-Alonso, MJ, Santamaria-Nuñez, G, Torralba, D, Alamo, P, Gallardo, A, Oliva, MA, Mangues, R, Diaz, JF, Cuevas, C. PM534, a Novel Colchicine Site Tubulin Inhibitor with Broad-Spectrum and Resistance-Overcoming Antitumor Activity. MOLECULAR CANCER THERAPEUTICS. 2026; 25(6)DOI:10.1158/1535-7163.MCT-25-0559. PMID:41481906. IF:5.500(Q1/2D).

Bartoletti, M, Del Turco, ER, Bussini, L, Paul, M, Sabik, EF, Castagna, A, Ripa, M, Gomes, MZR, Di Bella, S, Malosso, M, Lopez, AB, Franceschini, E, Bandera, A, Barbieri, V, Oliva, A, Munoz, P, Mularoni, A, Seminari, E, Morelli, P, Tascini, C, Papadimitriou-Olivgeris, M, Coppola, N, Cristini, F, Russo, A, Bassetti, M, Travi, G, Contreras, JL, Varisco, B, Viale, P, Cento, V, Gaibani, P, Bavaro, DF, Giannella, M. Monotherapy vs. combination therapy for Enterococcus faecalis bacteraemia: a target trial emulation. CLINICAL MICROBIOLOGY AND INFECTION. 2026; 32(6)DOI:10.1016/j.cmi.2026.03.018. PMID:41850617. IF:8.500(Q1/1D).

Hornuss, D, Mathé, P, Giesen, R, Escolà-Vergé, L, Isler, B, Bartoletti, M, Lamy, B, Wagner, D, Kern, WV, Rieg, S. Quality indicators for clinical infectious diseases consultations?results from a hybrid Delphi-nominal group approach and scenario study. CLINICAL MICROBIOLOGY AND INFECTION. 2026; 32(6)DOI:10.1016/j.cmi.2026.03.006. PMID:41831716. IF:8.500(Q1/1D).